Dr. Govindan on the Future of EGFR-Mutant NSCLC

Ramaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non—small cell lung cancer (NSCLC).

Clinical practice is already changing, Govindan says, as physicians are biopsying patients at the time of disease progression and obtaining cell-free DNA analyses. Moreover, second-line therapy is being decided based on gene alterations.

Secondly, Govindan explains that there is a good strategy in place for at least half of the patients who progress beyond the first-generation EGFR inhibitor. In the coming years, investigators will find a way to combine various agents and, hopefully, come up with novel agents that move downstream to work alongside EGFR inhibitors, as well.